ライフサイエンスコーパス: strut

1 (energy transfer between adjacent porphyrin struts).

2 ell-arranged one-dimensional units (nanotube struts).

3 rosclerosis, uncovered strut, and malapposed strut.

4 trut and extends drug delivery between stent struts.

5 phenyl)benzene and trans-1,2-dipyridylethene struts.

6 ST was the ratio of uncovered to total stent struts.

7 biodegradable polymer coating and ultra-thin struts.

8 tely healed neointimal layer overlying stent struts.

9 on the relative positioning of drug-eluting struts.

10 Malapposed struts (1.2% versus 0.3%; P=0.02) and malapposition leng

11 4.5%), neoatherosclerosis (27.6%), uncovered struts (12.1%), and stent underexpansion (6.9%).

12 Thick-strutted (162 mum) stents were 1.5-fold more thrombogeni

13 was neoatherosclerosis (31.3%) and uncovered struts (20.2%).

14 he maximal length of malapposed or uncovered struts (3.40 mm; 95% confidence interval, 2.55-4.25; ver

15 e most common dominant finding was uncovered struts (33.3%) and severe restenosis (19.1%); and for ve

16 At 5 years, uncovered struts (4.1% versus 1.0%; P<0.01), length of uncoverage

17 at maximum interstrut angle, and fewer stent struts (4.9+/-1.0 versus 6.0+/-0.5; P<0.01) even when no

18 ation of a symmetrical urea tetracarboxylate strut, 4,4'-bipyridine, and Zn(NO(3))(2).6H(2)O under so

19 significantly lower proportion of uncovered struts; 4.3% [interquartile range, 1.2-9.8] versus 9.0%

20 .02 to 0.09 mm), the prevalence of uncovered struts (49%; IQR, 16% to 96%), fibrin deposition (63+/-2

21 e tomography end point (percentage uncovered struts 5.64+/-9.65% in BMS+DEB versus 4.93+/-9.29% in DE

22 OF that are composed of two Zn(II) porphyrin struts [5,15-dipyridyl-10,20-bis(pentafluorophenyl)porph

23 ndomly assigned (2:1) to either an ultrathin strut (60 mum) bioresorbable polymer sirolimus-eluting s

24 to assess the long-term effect of ultrathin-strut (60 mum) BP-SES versus thin-strut (81 mum) DP-EES

25 e most common dominant finding was uncovered struts (61.7%) and underexpansion (25.5%); for late ST,

26 nding adjudicated for acute ST was uncovered struts (66.7% of cases); for subacute ST, the most commo

27 demonstrated a higher percentage of embedded struts (71.0% [47.6, 89.1] compared with BVS 40.3% [20.5

28 The TAXUS Element is a novel thin-strut (81 microm), platinum chromium alloy PES designed

29 ultrathin-strut (60 mum) BP-SES versus thin-strut (81 mum) DP-EES on long-term outcomes in patients

30 e thrombogenic than otherwise identical thin-strutted (81 mum) devices in ex vivo flow loops (P<0.001

31 m [IQR, 0.07 to 0.21 mm], P=0.008; uncovered struts: 9% [IQR, 0% to 39%], P=0.01; fibrin: 36+/-27%, P

32 The number and distribution of stent struts affect the amount of neointima after SES implanta

33 minimal in stents with 180/100 and 70/70 mum struts after embedding.

34 ng"--incomplete apposition of SB or MV stent struts against the MV wall proximal to the carina--was s

35 At all time points, the struts along the patent portions of the aneurysm necks h

36 and H2N-Cys-His-Asp-CONHL (where L = organic struts) amino acid sequences by covalently attaching the

37 e drug pellet no longer being affixed to the strut and categorized as spontaneous or surgically relat

38 e load of drug immediately around each stent strut and extends drug delivery between stent struts.

39 Protruding strut and strut malapposed with moderate detachment (ISA

40 viscous solutions of metal node and organic strut and subsequent evaporation of a plasticizer-modula

41 ion-based correlations between the converter/strut and the nucleotide-binding pocket, revealing a sur

42 gative density-based correlation between the strut and the nucleotide-binding pocket, which is consis

43 Eighty-two percent of uncovered struts and 99% of covered struts were labeled correctly,

44 n intricate network of highly interconnected struts and channels that not only ensure extraordinary s

45 Composed of discontinuous struts and continuous cables, such systems are only stru

46 Similarly, uncovered struts and fibrin deposition was significantly greater a

47 her than concentrating drug around the stent struts and for its ability to match coating erosion with

48 tal-organic framework (MOF) with porphyrinic struts and Hf6 nodes is reported.

49 ge with extensive segments of double-layered struts and inappropriately apposed struts at the bifurca

50 th larger amount of uncovered and malapposed struts and similar rate of neoatherosclerosis as compare

51 Malapposed struts and stent underexpansion were more frequently dem

52 The percentages of malapposed struts and struts being both uncovered and malapposed at

53 ime intervals from index stenting: uncovered struts and underexpansion in acute/subacute ST and neoat

54 vered cells were found attached to the stent struts and were also distributed within the adjacent den

55 onnect 2D sheets of 9,10-dicarboxytriptycene struts and Zn(2)(CO(2))(4) secondary binding units.

56 dings, such as neoatherosclerosis, uncovered strut, and malapposed strut.

57 Neointimal area, uncovered struts, and fibrin deposition were significantly higher

58 IH at maximum interstrut angle, fewer stent struts, and larger maximum interstrut angle.

59 malapposition, neoatherosclerosis, uncovered struts, and stent underexpansion without differences bet

60 ned the presence of tissue coverage for each strut; and estimated the stent contour for comparison of

61 MRI provided anatomic confirmation of stent strut apposition and functional corroboration of aneurys

62 We used long organic struts (approximately 2 nanometers) incorporating 34- an

63 onsist of periodic arrangements of nodes and struts are lightweight and can exhibit combinations of p

64 Tensegrity structures with detached struts are naturally suitable for deployable application

65 the vicinity of SMC-rich neointima and peri-strut areas.

66 can dislocate spontaneously from the suture strut as a late event that typically occurs after 3 year

67 pontaneously dislocated away from the suture strut at a mean postimplantation time of 77.4 months (ra

68 solution; (4) percentage of malapposed stent struts at 6 months; (5) 6-month restenosis; and (6) 6-mo

69 th BMS was associated with greater uncovered struts at flow divider sites, which is likely due to flo

70 e-layered struts and inappropriately apposed struts at the bifurcation level in 3 of 5 cases.

71 ciple that these stents are superior to thin-strut bare-metal stents for preventing repeat revascular

72 The percentages of malapposed struts and struts being both uncovered and malapposed at follow-up

73 vered within, adjacent, or without the stent struts being present in the RA.

74 largely comparable at all time points, with struts being sequestered within the neointima.

75 pocket, the relay helix, the SH1 helix, the strut between the upper 50 kDa and the lower 50 kDa subd

76 interlocked molecule (MIM) as the pillaring strut between two periodic Zn-carboxylate layers.

77 m stent is noninferior to a modern ultrathin strut biodegradable polymer cobalt-chromium sirolimus-el

78 , thick-strut fully bioabsorbable EES, thick-strut biodegradable polymer metallic biolimus-eluting st

79 enicity and re-endothelialization among thin-strut biodegradable polymer metallic everolimus eluting

80 llocating in a 1:1 ratio to either ultrathin-strut biodegradable polymer MiStent sirolimus-eluting st

81 ls have demonstrated the superiority of thin-strut biodegradable polymer second-generation drug-eluti

82 specified subgroup analysis of the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Vers

83 Ultrathin strut biodegradable polymer sirolimus-eluting stents (BP

84 red with DP-DES and more effective than thin-strut BMS, but without evidence for better safety nor lo

85 -(4-carboxyphenyl)porphyrin]Co(III) (CoTCPP) struts bound by linear trinuclear Co(II)-carboxylate clu

86 ive incidence, 22.3%) treated with ultrathin-strut BP-SES and 109 patients (18.3%) treated with thin-

87 e similar in patients treated with ultrathin-strut BP-SES and thin-strut DP-EES.

88 small vessel disease treated with ultrathin-strut BP-SES versus thin-strut DP-EES.

89 beneath regions of arterial contact with the strut but surprisingly also beneath standing drug pools

90 diac cycles were measured to describe the 3D strut, cell, section, and stent configuration.

91 Damage is therefore likely to accumulate in strut centers making cancellous bone more tolerant of st

92 The strut chordae were encircled with exteriorized wire snar

93 utions of the anterior leaflet second-order "strut" chordae are unknown.

94 adable polymer drug-eluting stents: the thin-strut cobalt-chromium sirolimus-eluting Orsiro stent and

95 Regarding this, the thin-strut CoCr-EES has consistently been associated with the

96 Simulations that coupled strut configurations with flow dynamics correlated with

97 ough both PES and SES showed nearly complete strut coverage after 12 months for on-label use, the maj

98 In this randomized trial, strut coverage and neointimal proliferation of a therapy

99 Strut coverage at 3 months of single implanted stents (n

100 is optical frequency domain imaging-assessed strut coverage at 3 months.

101 myocardial infarction would provide improved strut coverage at 6 months in comparison with angiograph

102 biolimus-eluting stent implantation improves strut coverage at 6-month follow-up in comparison with a

103 achment <100 mum at baseline showed complete strut coverage at follow-up, whereas segments with a max

104 -wall ISA distance on the risk of incomplete strut coverage at follow-up.

105 Flow disturbances and risk of delayed strut coverage both increase with ISA detachment distanc

106 gy to determine the optimal cutoff value for strut coverage by OCT which was defined as luminal endot

107 utoff value of neointimal thickness of stent strut coverage by OCT with histology confirmation.

108 Incomplete strut coverage has been documented an important histopat

109 Good stent strut coverage of >94% was found in both therapy groups.

110 Strut coverage of combined single and overlapped stents

111 ISCOVERY 1TO3 study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Bio

112 most accurate cutoff value to identify stent strut coverage validated by histology.

113 In vivo impact on strut coverage was assessed retrospectively using optica

114 Nearly complete strut coverage was observed in this complex population v

115 CoCr-EES demonstrated greater strut coverage with less inflammation, less fibrin depos

116 ants in which fibrin deposition, endothelial strut coverage, inflammatory response, and mechanism(s)

117 luting technology allows complete very early strut coverage.

118 at had developed in the place of side-branch struts, creating a neo-carina.

119 updates in the hardware itself, focusing on strut design.

120 miscalled as struts giving 1% false-positive strut detection.

121 etry of the olefinic axis of the interlocked struts determined the obtention of materials with differ

122 ted the guidewire, lumen boundary, and stent struts; determined the presence of tissue coverage for e

123 ristic sample sizes (film thickness, wire or strut diameter, ribbon width, particle diameter, etc), a

124 ains with dimensions similar to the fiber or strut diameters and in thin plates where grain diameters

125 CoCrFeNi micro-lattices are created with strut diameters as low as 100 mum and excellent mechanic

126 -generation DES were introduced with thinner struts, different scaffold designs (to improve deliverab

127 owed that more than the scaffold pattern and struts dimension, the selection of proper biomaterials i

128 bable scaffolds (BRS) is highly dependent on strut dimensions and polymer features.

129 However, strut dimensions and positioning relative to the vessel

130 Struts discernible on optical coherence tomography at 6

131 cases, malapposition by OCT in 5 of 9 cases, strut discontinuity in 2 of 9 cases, and underexpansion

132 also beneath standing drug pools created by strut disruption of flow.

133 To assess stent strut distribution, the maximum interstrut angle was mea

134 S and 109 patients (18.3%) treated with thin-strut DP-EES (rate ratio, 1.22; 95% CI, 0.94-1.58; P=0.1

135 ated with ultrathin-strut BP-SES versus thin-strut DP-EES.

136 treated with ultrathin-strut BP-SES and thin-strut DP-EES.

137 assessed noninferiority of a novel ultrathin strut drug-eluting stent releasing sirolimus from a biod

138 nts treated with ultrathin-strut versus thin-strut drug-eluting stent.

139 rae (window-like openings) separated by bony struts (e.g., lizards, tuatara, dinosaurs and crocodiles

140 Transversely oriented struts enhance resistance to fatigue by acting as sacrif

141 form a complete neointimal layer over stent struts) extends the window during which stents are prone

142 l-type nodes and 1,3,5-benzenetricarboxylate struts, features accessible Cu(II) sites to which solven

143 Meta-analyses have shown that the thin-strut, fluoropolymer-coated cobalt-chromium everolimus-e

144 Stent fracture was graded as I (single-strut fracture), II (> or =2 struts), III (> or =2 strut

145 By December 2003, outlet strut fractures (OSFs), often with fatal outcomes, had b

146 ld distortion at the bifurcation with single strut fractures in 4 of 5 and double fractures in 1 of 5

147 in 3 of 5 T-and protrusion procedures single strut fractures were noted.

148 On microcomputed tomography, no strut fractures were present after modified-T, whereas i

149 e 27 procedures, dissociation of the implant strut from the drug-containing cup occurred in 11 eyes (

150 allic everolimus eluting stents (EES), thick-strut fully bioabsorbable EES, thick-strut biodegradable

151 oftware and some artifacts were miscalled as struts giving 1% false-positive strut detection.

152 lialization and neointimal coverage on stent struts has been put forward as the main underlying mecha

153 Struts have been considered as covered when tissue overl

154 rials comprising inorganic nodes and organic struts, have potential application in many areas due to

155 a more favorable biomechanical behavior and strut healing profile compared with BVS in normal porcin

156 Scaffold strut healing was evaluated in vivo using weekly optical

157 nd surfaces, as demonstrated with thin stent struts, help reduce the potential for thrombosis despite

158 ingly different between platforms; localized strut hypersensitivity was exclusive to SES, whereas mal

159 ed as I (single-strut fracture), II (> or =2 struts), III (> or =2 struts with deformation), IV (with

160 ign of organic building blocks, which act as strut-impervious scaffolds, can be exploited to generate

161 an overcrowded alkene-based molecular motor strut in a dual-function metal-organic framework (MOF) i

162 s been developed and the arene employed as a strut in the synthesis of P5A-MOF-1, which has been demo

163 unded by thrombus in 7.1%, 9.0%, and 8.9% of struts in cases 1, 2, and 4, respectively.

164 cute ST and neoatherosclerosis and uncovered struts in late/very late ST.

165 ic order and site isolation of the catalytic struts in MOFs facilitate the studies of their activitie

166 ug-induced fibrin deposition surrounding DES struts in porcine coronary arteries.

167 Scaffold discontinuity with struts in the lumen center was the cause of malappositio

168 by covalently attaching them to the organic struts in the MOFs, without losing porosity or crystalli

169 6 months, the percentage of malapposed stent struts in the MTA arm was higher than in the RT arm (2.7

170 Adjacent and overlapping stent struts increased computed arterial drug deposition by fa

171 e in risk for LST as the number of uncovered struts increased.

172 ced glycation end products compared with the strut interior.

173 yl)-terpyridine)ruthenium(II) (Ru(cptpy)(2)) strut into a robust metal-organic framework (MOF), AUBM-

174 he 24C6 macrocyclic ring of the pillared MIM strut is now free enough to undergo full rotation.

175 is not repeated in a given octahedron, each strut is uniquely addressable by the appropriate sequenc

176 sidered as covered when tissue overlying the struts is >0 mum by optical coherence tomography (OCT).

177 Because the base-pair sequence of individual struts is not repeated in a given octahedron, each strut

178 Strut junction interactions affect local directional per

179 Reaction of a ditopic urea "strut" (L1) with cis-(tmen)Pd(NO3)2 yielded a [3+3] self

180 e bifurcation coverage and in minimal double-strut layers at the neocarina.

181 Overlapping stent struts lead to localized peaks of drug concentration tha

182 s during crystal growth, the relatively soft strut lengths and diameters of the double-gyroid network

183 cal coherence tomography, which also enables strut-level assessment due to its higher axial resolutio

184 Strut-level neointimal thickness was 0.19+/-0.09 mm and

185 Strut-level tissue thickness, tissue coverage area, and

186 A-binding domains located at each end of its strut-like structure.

187 Protruding strut and strut malapposed with moderate detachment (ISA detachmen

188 The most frequent findings were strut malapposition (34.5%), neoatherosclerosis (27.6%),

189 Extensive strut malapposition was the presumed cause for ScT in 1

190 ere related to (1) stent underexpansion, (2) strut malapposition, (3) edge dissection(s), and (4) res

191 The MGuard is a novel thin-strut metal stent with a polyethylene terephthalate micr

192 biphasic relationship between cell speed and strut modulus and also indicated that mechanical factors

193 in-cap NA), II (thick-cap NA), and III (peri-strut NA).

194 is identified the number of visualized stent struts normalized for the number of stent cells and maxi

195 The process of crack propagation within the struts of a foam is not well understood and is complicat

196 ing of the chemical composition of pore-wall struts of CSi scaffolds is beneficial for enhancing the

197 via the midline central stem and the lateral struts of the vault cartilages.

198 nds to reduce ISA, with the malapposed stent struts often integrated completely into the vessel wall,

199 t the DNA strands fold successfully, with 12 struts or edges joined at six four-way junctions to form

200 Formation of a novel bone strut, or a bone bridge connecting the Op and BR togethe

201 fectly aligned fibers giving rise to fibrous strut orientation, variable inter-strut pore size and co

202 nts were percent of uncovered and malapposed struts over time.

203 architectures composed of closed-cell porous struts patterned in the form of hexagonal and triangular

204 incomplete apposition; 4) restenosis; and 5) strut penetration into a necrotic core.

205 iate analysis revealed that maximal depth of strut penetration, % strut with medial tear, and % strut

206 mm; P=0.02), and ratio of uncovered to total struts per cross-section >/=30% (35.5% versus 9.7%; P=0.

207 e to compare the ratio of uncovered to total struts per cross-section >/=30% and other optical cohere

208 ile range] of uncovered and malapposed stent struts per lesion was 0 [0 to 0.35], 2.84 [0 to 6.63], a

209 ent with a ratio of uncovered to total stent struts per section >30% is 9.0 (95% CI, 3.5 to 22).

210 ion versus ratio of uncovered to total stent struts per section demonstrated a marked increase in ris

211 on was the ratio of uncovered to total stent struts per section.

212 ppearance of tip embedding, degree of filter strut perforation, and distance of filter tip from the n

213 r MiStent sirolimus-eluting stent or to thin-strut permanent polymer Xience everolimus-eluting stent.

214 to fibrous strut orientation, variable inter-strut pore size and controlled film width (via layering)

215 o drug delivery depends on clot geometry and strut position in clot relative to the vessel wall.

216 01, its pseudorotaxanes, and their molecular strut precursors.

217 s are a blueprint for applying the 'node and strut' principles of reticular synthesis to molecular cr

218 ing stent and the noninferiority to the thin-strut second-generation permanent polymer drug-eluting s

219 nd 2012 were reviewed for drug pellet-suture strut separation, observed before surgery in clinic or o

220 de a framework (MOF-177) devoid of polyether struts showed negligible uptake of PQT2+, indicating the

221 eneration everolimus-eluting DP-DES, or thin-strut silicon-carbide-coated BMS in 8 European centers.

222 The thin-strut sirolimus-eluting Orsiro stent was noninferior to

223 Each connector has up to four struts, so that a single connector can link up to four M

224 phorylcholine polymer on a cobalt alloy thin-strut stent has shown promising experimental and early c

225 , the crush technique with the use of a thin-strut stent may result in improved immediate hemodynamic

226 Moreover, both studies used thick-strut stents known to have high restenosis rates as cont

227 Struts still recognizable on optical coherence tomograph

228 mum and >300 mum had 6.1% and 15.7% of their struts still uncovered at follow-up, respectively (P<0.0

229 osomes, suggesting that microtubules act as "struts" stretching the spindle matrix.

230 ribution of junction points between scaffold struts strongly modulates motility.

231 The thin-strut structure of the stent platform, the thromboresist

232 biodegradable polymer coating and ultra-thin struts (Supraflex) or an everolimus-eluting stent with a

233 dition, drug eluted from the abluminal stent strut surface accounted for only 11% of total deposition

234 ne more tolerant of stress concentrations at strut surfaces.

235 ug load or arterial wall contact with coated strut surfaces.

236 rties associated with increased ductility of strut surfaces.

237 OCT showed malapposed scaffold struts surrounded by thrombus in 7.1%, 9.0%, and 8.9% of

238 induced more uncovered and malapposed stent struts than BMS, but less than after DES.

239 nsive regulatory segments form a coiled-coil strut that blocks peptide and ATP binding to the otherwi

240 ance to blood flow as compared with floating strut that has more significant ISA distance.

241 proposed to act mechanically as compressive struts that resist both actomyosin contractile forces an

242 rolimus-eluting stent (BP-SES; 60 and 80 mum strut thickness for stent diameters <=3 and >3 mm, respe

243 panding endovascular stent was designed with strut thickness of 70 mum x 70 mum width.

244 nd failed to specify the impact of ultrathin-strut thickness on long-term clinical outcomes compared

245 Despite a similar scaffold strut thickness, the Magmaris sirolimus-eluting bioabsor

246 rformed to study the efficacy of stents with struts (thickness/width) 70/70, 180/100 and 300/150 mum

247 cobalt porphyrin catalysts linked by organic struts through imine bonds, to prepare a catalytic mater

248 separated, but not dislocated away, from the strut; time to exchange of dislocated or dissociated pel

249 Upon reduction of the metalloporphyrin struts to (Co(I)TCPP)CoPIZA, the CoPIZA thin film demons

250 e to compare patients treated with ultrathin-strut versus thin-strut drug-eluting stent.

251 cified noninferiority margin of 5% uncovered struts versus DES (difference between treatment means, 0

252 on in different cases of ISA with increasing strut-wall detachment distance (ranging from 100 to 500

253 age revealed an important impact of baseline strut-wall ISA distance on the risk of incomplete strut

254 support strut was used for 66 patients; the strut was placed anterior to the sternum in 9 patients u

255 The strut was routinely removed within 6 months.

256 A substernal support strut was used for 66 patients; the strut was placed ant

257 que and/or thrombus protrusion through stent struts was initially present in 70.4% of PES and 64.8% o

258 ogenicity of polymer-coated stents with thin struts was lowest in all configurations and remained ins

259 complete endothelialization over the device struts was present.

260 The percentage of uncovered struts was similar between SES and PES including stents

261 groups, whereas the percentage of uncovered struts was strikingly lower in CoCr-EES (median=2.6%) ve

262 The percentage of acutely malapposed struts was substantially lower in the OCT-guided group (

263 y distal to individual isolated drug-eluting struts was twice as great as in the proximal area and fo

264 ed as ISA volume or maximum ISA distance per strut) was an independent predictor of ISA persistence a

265 erations and location of drug elution on the strut were far more important in determining arterial wa

266 In lesions B, uncovered struts were 2.91+/-5.47% at 6-months.

267 Malapposed struts were 3.55+/-5.16% at post-procedure, 1.51+/-3.52%

268 In lesions A, uncovered struts were 3.77+/-4.94% and 3.02+/-4.35% at 3 versus 9

269 Malapposed struts were 4.94+/-6.70% post-procedure and 1.01+/-3.11%

270 nts presenting very late ST, uncovered stent struts were a common dominant finding in drug-eluting st

271 actor centered on the stent, and the visible struts were counted and normalized for the number of ste

272 uts were identified as uncovered, while 1056 struts were covered.

273 n patients with ST, uncovered and malapposed struts were frequently observed with the incidence of bo

274 By histology, 160 struts were identified as uncovered, while 1056 struts w

275 In all patients, BVS struts were integrated in the vessel and were not discer

276 rcent of uncovered struts and 99% of covered struts were labeled correctly, as compared to manual ana

277 Eleven percent of struts were missed by the software and some artifacts we

278 Uncovered and malapposed struts were more frequent in thrombosed compared with no

279 At 5 years, struts were no longer discernable by OCT and IVUS.

280 Uncovered and malapposed struts were observed in 70.5% (43/61) and 62.3% (38/61)

281 A total of 2235 struts were reviewed by histology, 1216 were considered

282 At 21 days, uncovered struts were still present in the BVS group (3.8% [2.1, 1

283 nations, only small remnants of the original struts were visible, well embedded into the intima.

284 med" myosin heads may function as "transient struts" when attached to the thin filaments.

285 tology, 1216 were considered as well-matched struts which were analyzed in this study.

286 pendent strengthening of load-bearing nickel struts whose diameter is as small as 17 nm and whose 8 G

287 be coupled to prepare the requisite organic strut with four metal-binding sites in the form of four

288 d that maximal depth of strut penetration, % strut with medial tear, and % struts with incomplete app

289 d by the lack of contact of at least 1 stent strut with the vessel wall in a segment not overlying a

290 g Fantom, incorporates a radiopaque polymer, struts with a thickness of 125 um, and a crossing profil

291 fracture), II (> or =2 struts), III (> or =2 struts with deformation), IV (with transection without g

292 penetration, % strut with medial tear, and % struts with incomplete apposition were the primary indic

293 Uncovered scaffold struts with superimposed thrombus were the predominant f

294 in particular, at the contacts of the stent struts with the artery.

295 ssociations of both uncovered and malapposed struts with thrombus were consistent among early- and ne

296 s over a net distance of up to ~45 porphyrin struts within its lifetime in DA-MOF (but only ~3 in F-M

297 Pellets also may be dissociated from the strut without dislocation, when separation occurs at the

298 n Fe-decorated Hf6 node and the Fe-porphyrin strut work in concert.

299 Directly testing the effects of varying strut Young's modulus on cell motility showed a biphasic

300 ic framework with Lewis acidic (porphyrin)Zn struts, ZnPO-MOF, can be made in high yields.